Moderna booster shot data reports improved protection against S.African and Brazil variant: Doubles antibody production


On Wednesday, Moderna (NASDAQ: MRNA) released early data on the efficacy of its booster shot. The reports indicated that the subjects who got a third shot of either the original or the booster shot had a larger number of antibodies when compared with those who took the usual two doses. After six months, the booster shot was able to block twice as much of the variants when compared to those who got a third dose.

Moderna is the first company to release data about its booster shot. Although the results are promising the following points have to be noted:


  • It’s a small trial sample of 40
  • Tests and trials were done at lab level
  • No clinical trials have been done, as yet
  • No real-world data can be obtained at this early stage


The company has not mentioned the time period within which it would apply for emergency use by the Food and Drug Administration (FDA). The agency has already indicated that booster shots will not be required to undergo as stringent testing procedures as the original COVID-19 vaccine doses.  The current vaccine rollout across the nation has slowed down. This could lead to a longer period of time for the nation to achieve herd immunity. This would facilitate the emergence of new variants as the virus keeps evolving.


It will become necessary to keep on researching to formulate new booster shots of the COVID-19 vaccine for it to keep up with the emerging coronavirus variants. The body’s immune system can also be stimulated by the original vaccine so that it can put up a better fight against the new variants. Vaccines boost the production of antibodies in the human body. However, there are also several other key factors present in humans that help the body survive against attacks from foreign bodies, one of which is the coronavirus.

  • Follow us on Google news for more updates and News


    This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

    Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

    Full Disclaimer

    %d bloggers like this: